Biofrontera Inc. 8-K

What Happened

• Biofrontera Inc. announced the results of its Phase 2b clinical study of Ameluz® photodynamic therapy (PDT) for the treatment of moderate to severe Acne Vulgaris. The company furnished a press release with these results as Exhibit 99.1 to a Form 8-K filed on March 9, 2026 under Item 7.01 (Regulation FD Disclosure).

Key Details

• Filing date: March 9, 2026 (Form 8-K, Item 7.01, Regulation FD Disclosure).
• Study: Phase 2b clinical trial of Ameluz® PDT for moderate to severe Acne Vulgaris.
• Disclosure format: Results announced in a press release, furnished as Exhibit 99.1 and incorporated by reference in the 8-K.
• The Form 8-K also includes the interactive XBRL cover page (Item 9.01 exhibits list).

Why It Matters

• Clinical trial results are key milestones for a development-stage or specialty pharmaceutical product; the announced Phase 2b data advance public understanding of Ameluz’s clinical progress in a new dermatology indication.
• Investors should review the press release (Exhibit 99.1) for the full data and any company commentary, as those details can affect assessments of Ameluz’s regulatory path, potential commercial opportunity, and the company’s near-term news flow.